Polaris Market Research Releases Radiotheranostics Market Outlook 2026-2034: Radioligand Therapies Drive Precision Oncology

New industry analysis projects a USD 24.21 Billion radiotheranostics market by 2034 as expanding radioligand therapy adoption, targeted alpha therapy development, and radioisotope production investments strengthen precision oncology.

Market Size 2025	Forecast 2034	CAGR 2026-2034	Leading Region
USD 10.80 Billion	USD 24.21 Billion	9.4%	North America

Polaris Market Research & Consulting has released its Radiotheranostics Market Report 2026-2034. The market was valued at USD 10.80 billion in 2025 and is projected to reach USD 24.21 billion by 2034, registering a CAGR of 9.4% during the forecast period. The growth of market is driven by rising number of approvals for radioligand therapy, increasing use of Lutetium-177 for treatment of prostate cancer and neuroendocrine tumor, and growing investments in radiopharmaceutical manufacturing and medical isotopes production.

Recent trends within the industry strengthen commercial potential of radiotheranostics market. In May 2026, Novartis got MHRA approval in the UK for an extended indication for Pluvicto in PSMA-positive metastatic castration-resistant prostate cancer. In June 2026, Telix Pharmaceuticals signed a long-term contract for provision of Actinium-225 with the Australian Nuclear Science and Technology Organisation (ANSTO) in order to boost its pipeline of targeted alpha therapy. In May 2026, Oak Ridge National Laboratory (ORNL) launched a new project on research and production of alpha-emitting radioisotopes for targeted alpha therapy.

“Radiotheranostics is transforming precision oncology through the use of precise diagnostics along with personalized radioligand therapy. Companies which enhance their capabilities with respect to isotopes, manufacturing facilities, clinical evidence, and treatment facilities will be in a good position as the use of radiopharmaceuticals grows further.”  — Prajakta Bengale, Senior Healthcare Analyst

Radiotheranostics Market Investment Signals 2026

Investment Theme	Market Signal	Business Implication
Radioligand Therapy Expansion	Novartis expanded the approved indication for Pluvicto in the UK	Supports broader clinical adoption of PSMA-targeted radioligand therapies
Radioisotope Supply Capacity	Telix Pharmaceuticals signed a long-term Actinium-225 supply agreement with ANSTO	Strengthens long-term isotope availability for targeted alpha therapy programs
Targeted Alpha Therapy Development	ORNL launched an initiative to expand production and research of alpha-emitting radioisotopes	Supports future commercialization of next-generation radiopharmaceuticals
Manufacturing & Infrastructure Investment	Continued investment in radiopharmaceutical manufacturing and isotope production	Improves long-term supply reliability and supports commercial market expansion

Source: Polaris Market Research Analysis

Three Market Developments Reshaping the Radiotheranostics Industry in 2026

Radioligand Treatments are Gaining More Clinical Ground

Increasing number of approvals and indications for radioligand treatments are fueling the market growth. Pluvicto's extension into other patient groups is a result of growing trust in precision oncology treatments that integrate molecular imaging with targeted therapy.

Actinium-225 Is Strengthening the Next Phase of Market Growth

Targeted alpha therapy continues to play an increasingly prominent role in the development of new radiotheranostics treatments. Investments in the production and manufacturing of Actinium-225 ensure the development of next-gen treatments and satisfaction of future isotopes' needs.

Manufacturing Capacity Is Becoming a Strategic Competitive Advantage

As demand for radiotheranostic therapies continues to increase, reliable radioisotope production and radiopharmaceutical manufacturing are becoming critical differentiators. Investments across isotope production, radiopharmacy infrastructure, and specialized treatment networks are strengthening the industry's ability to support broader clinical adoption across oncology care.

Request a free sample copy or read the full market insights : Radiotheranostics Market Report

About the Polaris Radiotheranostics Market Report 2026-2034

The report provides comprehensive analysis of market size, segmentation, regional trends, competitive landscape, and technology developments across the global radiotheranostics ecosystem. It is designed for pharmaceutical companies, radiopharmaceutical manufacturers, radioisotope producers, hospital networks, cancer centers, investors, and government agencies seeking strategic insights into market opportunities, technology innovation, and competitive positioning.

Report coverage: Market size and CAGR by radioisotope, application, and end user | Regional analysis across 5 regions with country-level breakdowns | Competitive landscape and company benchmarking | Technology and innovation assessment | Regulatory environment analysis | PDF and Excel formats | Customization available by country, region, and segment

Key Companies Profiled

• Novartis AG
• Bayer AG
• Lantheus Holdings Inc.
• Telix Pharmaceuticals Limited
• Curium Pharma
• ITM Isotope Technologies Munich SE
• Eli Lilly and Company
• Bristol Myers Squibb Company
• AstraZeneca plc
• Fusion Pharmaceuticals Inc.
• Point Biopharma Global Inc.
• RadioMedix Inc.
• RayzeBio Inc.

Market Segments Covered in the Radiotheranostics Market Report

By Radioisotope Outlook (Revenue, USD Billion, 2021–2034)

• Lutetium-177
• Actinium-225
• Gallium-68
• Radium-223
• Others

By Application Outlook (Revenue, USD Billion, 2021–2034)

• Prostate Cancer
• Neuroendocrine Tumors
• Other Solid Tumors
• Hematologic Malignancies
• Others

By End User Outlook (Revenue, USD Billion, 2021–2034)

• Hospitals
• Cancer Centers
• Imaging Centers
• Specialty Clinics
• Others

By Regional Outlook (Revenue, USD Billion, 2021–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of Middle East & Africa